Susvimo Approval Expanded to Include Diabetic Macular Edema
The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.
Related Articles
Maladaptive Cardiovascular Reactivity to Mental Stress Linked to Adverse Outcomes
Risk score derived from cardiovascular reactivity predictive of adverse outcomes beyond traditional cardiovascular risk factors in CAD
Reply: Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial | Journal of Urology
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
Acute Toxicity Linked to Late Toxicity After Radiation Therapy for Prostate Cancer
Acute toxicity after radiotherapy is associated with late toxicity and quality of life in patients with prostate cancer, data suggest.
Dayna R. Smerina and Amy M. Pearlman, MD, discuss their research in sexual medicine
Smerina and Pearlman discuss recent research collaborations in the field of sexual medicine.
Immunogenic Cancer Vaccine Targets Key Mutations in Kidney Cancer
Personalized vaccine targets key driver mutations and induces antitumor immunity in fully resected high-risk clear cell renal cell carcinoma
EAU Guidelines on Prostate Cancer – TREATMENT – Uroweb
The Prostate Cancer (PCa) Guidelines Panel have prepared this guidelines document to assist medical professionals in the evidence-based management of PCa.
Biomarkers in advanced prostate cancer: Liquid biopsy, ctDNA, and more
“The management of advanced prostate cancer has evolved significantly, driven in part by the integration of diverse biomarkers that guide treatment decisions from diagnosis through…
Steroidal and Nonsteroidal MRAs Provide Variable Benefits in CKD, Dialysis
An umbrella review of steroidal and nonsteroidal mineralocorticoid receptor antagonists (MRA) support variable benefits in chronic kidney disease (CKD).
HERIZON-BTC-302: Zanidatamab for HER2-Positive BTC | Docwire News
Dr. Pant offered insights on the key findings of zanidatamab’s efficacy and safety in HER2-positive BTC.
Can the latest patient decision aid help OAB patients?
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Read our Cookies
